Bladder cancer is a heterogeneous group of tumours with at least 40 histological subgroups.
Patients with localized disease can be cured with surgical resection or radiotherapy, but …

Bladder cancer is an important public health concern owing to its prevalence, high
recurrence risk and treatment failures. Maintaining the equilibrium between prompt and …

All tumors accumulate genetic alterations, some of which can give rise to mutated, non-self
peptides presented by human leukocyte antigen (HLA) molecules and elicit T-cell …

Immunosurveillance, which describes the immunologically mediated elimination of
transformed cells, has been widely accepted in the context of bladder cancer for many …

Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed
for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and …

Bladder cancer is a prevalent but currently understudied cancer type and patient outcomes
are poor when it progresses to the muscle-invasive stage. Current research in bladder …

Tertiary lymphoid structures (TLSs) are associated with anti-tumor response following
immune checkpoint inhibitor (ICI) therapy, but a commensurate observation of TLS is absent …

Background The clinical benefit of immunotherapeutic approaches against cancer has been
well established although complete responses are only observed in a minority of patients …

Liquid biopsy technologies have seen a significant improvement in the last decade, offering
the possibility of reliable analysis and diagnosis from several biological fluids. The use of …

Simple Summary In contrast with other strategies, immunotherapy is a treatment aimed at
empowering the patient's immune system in order to increase immunity and the response …